Elizabeth Halloran
Associate Director of Evidence Synthesis
Expertise:
Elizabeth is an Associate Director of Evidence Synthesis at EVERSANA, with six years of experience conducting literature review and indirect treatment comparison projects. She has co-authored multiple publications and assisted in compiling evidence syntheses for health technology assessment submissions, across a variety of indications including gastroesophageal reflux disease, multiple sclerosis, and breast cancer. She holds a B.Sc. and M.Sc. in Chemical Biology from McMaster University. A list of Elizabeth’s publications can be found here.
Articles by Elizabeth Halloran
Comparing Long-Term HAE Treatments: Insights from a Robust Network Meta-Analysis
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent edema attacks in various parts of the body, including the extremities, face, gastrointestinal tract, and airway. While most current treatments can help relieve acute symptoms pf HAE, long-term prophylactic treatment plays a critical role in minimizing attack frequency and improving quality of life. Current […]
New Insights into Brain Volume Loss in MS
We are excited to announce that members of the EVERSANA team have contributed to a significant publication in BMC Neurology. The study, titled “Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies,” provides valuable insights into the effects of various treatments on brain volume loss (BVL) in patients with relapsing […]